U-AZN

Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - http://www.astrazeneca.com

09:07:34 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
AZN - Q	0.9	70.34	·	70.40	1.0	70.13			12.0	666	87		76.56 60.47	08:43:58	Apr 16	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 87

More trades...

Time ET	Ex	Price	Change	Volume
08:43:58	Q	70.39	0.26	200
08:43:03	Q	70.37	0.24	200
08:32:16	Q	70.40	0.27	200
08:32:16	Q	70.40	0.27	196
08:23:09	Q	70.365	0.235	1
08:16:33	Q	70.31	0.18	200
08:16:33	Q	70.31	0.18	63
08:16:33	Q	70.31	0.18	6
08:15:11	Q	70.31	0.18	6
08:13:48	Q	70.33	0.20	99

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-16 07:00	U:AZN	News Release200	IMFINZI(TM) (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
2024-04-11 07:00	U:AZN	News Release200	FASENRA approved for treatment of children aged 6 to 11 with severe asthma
2024-04-05 23:10	U:AZN	News Release200	ENHERTU(TM) Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
2024-04-05 21:43	U:AZN	News Release200	ENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
2024-04-05 07:00	U:AZN	News Release200	IMFINZI(TM) (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
2024-04-02 07:00	U:AZN	News Release200	Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2024-04-01 07:00	U:AZN	News Release200	VOYDEYA(TM) approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Date ET

Symbol

Type

Headline

2024-04-16 07:00

U:AZN

News Release

IMFINZI(TM) (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

2024-04-11 07:00

U:AZN

News Release

FASENRA approved for treatment of children aged 6 to 11 with severe asthma